A CloudMD Company
Sign in Get IMD Health

iMD Health is Pleased to Announce an Important Partnership Renewal with Apobiologix

Industry leading digital oncology platform extends important partnership, as pandemic fuels the surge for trusted education
April 19, 2021 – Toronto, Ontario

iMD Health Global (a CloudMD Software & Services company) (iMD) is pleased to announce an important partnership renewal with Apobiologix, Canada’s leader in Oncology biosimilars – to provide a unique, comprehensive digital platform to both providers and patients in oncology, at a time when digital solutions are in high demand and will be a solution in providing healthcare post pandemic. This partnership provides a comprehensive platform to improve health literacy, treatment options and treatment journey education resources, not only while on-site at oncology clinics, but also from the patient’s home.

Developed by working closely with Canadian oncology clinics, the platform has been custom tuned to the needs of frontline healthcare workers who are using the platform to inform and engage their patients. ”iMD Health has allowed us to engage patients more efficiently and has enabled the cancer care program at North York General Hospital (NYGH)  to move beyond paper based education materials.  The iMD team was, and continues to be, fantastic in providing personalization of the platform with NYGH-specific design that is very user friendly” said Mova Leung, Clinical Pharmacist Practitioner, NYGH.  “With the iMD platform, we now have a seamless, efficient way to deliver regimen-specific chemotherapy teaching videos to our patients without having to rely on complex instructions.  The feedback from patients has been great overall and certainly heightened during the pandemic where family members are not allowed to attend.” 

“We are proud to continue working with iMD. Over the past five years of our collaboration, the critical importance of digital health tools has only increased.  We are pleased to bring this educational platform to our oncology partners while improving patient’s overall satisfaction of care” said Mike Woolcock, Apobiologix Senior Vice-President. 

iMD Health is the largest digital health educational platform in Canada. iMD offers innovative technology that facilitates meaningful dialogue between healthcare professionals and patients inside the examination room, hospital clinics & bedsides and the during pharmacy consultations. iMD’s award winning platform enables healthcare providers to instantly access thousands of educational graphics, videos and resources at the point of care. To see iMD in action, CLICK HERE.“

We know that 83% of adults in Canada try to use the internet to self-diagnose, yet only about 3% of those findings are accurate. The need for trusted, accurate health information delivered through a digital platform from within clinic or at home – has never been stronger,” said Kevin Delano, CEO & President of iMD, “We are very excited to continue our partnership with Apobiologix whereby providing oncology focused healthcare providers and their patients with better access to their cancer details and treatment therapy information in a time when it is crucial to be properly informed.”

About Apotex Inc.

Apotex Inc. is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs almost 8,000 people worldwide in manufacturing, R&D, and commercial operations.  Apotex Inc. exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the US, Mexico, and India. Through vertical integration, Apotex is comprised of multiple divisions and affiliates including Apotex Inc., focused on generics; Apobiologix, a division of Apotex Inc. focused on biosimilar development; Aveva, an affiliate of Apotex Inc. fully integrated global developer and manufacturer of complete transdermal solutions; Apotex Consumer Products, a division of Apotex Inc. focused on brand name products; and Global Active Pharmaceutical Ingredients (GAPI), a division of Apotex Inc. focused on the manufacturing of active pharmaceutical ingredients (API) for Apotex and third parties. For more information visit: www.apotex.com.

For more information, contact Jordan Berman, VP Global Corporate Affairs  jberman@apotex.com

About iMD Health Global

iMD Health Global is a Toronto-based eHealth software development company, focused on innovating healthcare education. Since 2010, iMD has grown into Canada’s largest digital patient engagement platform. Centred “At The Point of Care”®, healthcare professionals use iMD’s cloud-based platform (in clinic or virtual consults) to engage with their patients at a deeper level and optimize knowledge transfer surrounding a patient’s condition and treatment plan. This is done through the seamless integration of over 80,000 images, booklets, and video resources, (covering 2,100 medical topics) into an award-winning user interface that makes patient education both efficient and effective. At the end of a patient’s consult, a summary of all the discussed information can be emailed to the patient to review and continue their learning journey at home, improving their health literacy and adherence to their treatment plan. The iMD platform is utilized by over 10,000 clinicians (doctor’s, nurses and pharmacists in, clinics, hospitals, pharmacies, infusion clinics and in homecare settings. For more information please visit: www.imdhealth.com and app.imdhealth.com.  iMD Health is a subsidiary of CloudMD Software & Services.

For more information, contact Jared Sonnenberg, VP  jared.sonnenberg@imdhealth.com

About CloudMD Software & Services (TSXV: DOC)

CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. By leveraging healthcare technology, the Company is building one, connected platform that addresses all points of a patient’s healthcare journey and provides better access to care and improved outcomes. Through CloudMD’s proprietary technology, the Company delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 7,000 psychiatrists, approximately 4,500 therapists and counsellors, approximately 4,000 psychologists, over 22,000 family physicians, over 34,000 medical specialists, over 1,500 allied health professionals, over 500 clinics, and over 5 million individuals across North America. CloudMD’s Enterprise Health Solutions Division includes one of the top 4 Employee Assistance Programs in Canada and offers one comprehensive, digitally connected platform for corporations, insurers and advisors to better manage the health and wellness of their employees and customers.

For more information visit: www.cloudmd.ca  For more information, contact Julia Becker, VP Investor Relations   julia@cloudmd.ca